FibroGen

FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones
FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones
Fierce Pharma
FibroGen
Thomas Neff
Pharma CEOs
roxadustat
Flag link:
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
Yahoo/Zacks.com
AstraZeneca
FibroGen
China
roxadustat
chronic kidney disease
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
Roxadustat safety analysis provokes more questions than answers
Roxadustat safety analysis provokes more questions than answers
EP Vantage
FibroGen
roxadustar
anemia
AstraZeneca
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
FDA
Novartis
Ascendis
Eiger BioPharmaceuticals
Proteostasis Therapeutics
Fibrocell Science
Supernus Pharmaceuticals
FibroGen
INSYS Therapeutics
Flag link:
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
CP Wire
FibroGen
pamrevlumab
IPF
idiopathic pulmonary fibrosis
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
FibroGen
pamrevlumab
idiopathic pulmonary fibrosis
Flag link:
Galapagos spotlights an ‘exciting’ round of PoC data for IPF drug, shares surge
Galapagos spotlights an ‘exciting’ round of PoC data for IPF drug, shares surge
Endpoints
Galapagos
IPF
GLPG1690
FibroGen
Flag link:
FibroGen Has The Look Of A Long-Term Biotech Winner
FibroGen Has The Look Of A Long-Term Biotech Winner
Seeking Alpha
FibroGen
roxadustat
kidney disease
Flag link:
9 Biotech Picks for 2016
9 Biotech Picks for 2016
Barron's
biotech
Adaptimmune
Dermira
FibroGen
Incyte
Intra-Cellular Therapies
Seres Therapeutics
Ophthotech
Neurocrine Biosciences
Paratek
Flag link:
IPO Stock Watch: FibroGen Up With Liver-Disease Field
IPO Stock Watch: FibroGen Up With Liver-Disease Field
Investors.com
IPOs
FibroGen
liver disease
NASH
Flag link:
Show me the money: Which drugs made the top 10 list on upfront deals?
Show me the money: Which drugs made the top 10 list on upfront deals?
Fierce Biotech
biotech
GED-0301
Celgene
Nogra Pharma
AbbVie
Reata
Bardoxolone
Abbott Labs
Tradjenta
Eli Lilly
Boehringer Ingelheim
FG-4592
AstraZeneca
FibroGen
Pfizer
Bristol-Myers Squibb
Eliquis
Moderna
Forma Therapeutics
dimebon
Medivation
Jakafi
Novartis
Incyte
Flag link:
FierceBiotech's 2013 Fierce 15
FierceBiotech's 2013 Fierce 15
Fierce Biotech
biotech
AnaptysBio
Acetylon Pharmaceuticals
CytomX
Immunocore
FibroGen
Jounce Therapeutics
Kala Pharmaceuticals
Macrogenics
Moderna Therapeutics
Presage Biosciences
Nimbus Discovery
Scioderm
Ultragenyx
uniQure
Visterra
Flag link:
Astellas, GSK vie to make 'high altitude' anemia pill
Astellas, GSK vie to make 'high altitude' anemia pill
Reuters
Astellas
GSK
anemia
GSK 1278863
FibroGen
FG-4592
Flag link:
FibroGen: Drug could reduce lung fibrosis
FibroGen: Drug could reduce lung fibrosis
Bizjournals.com
FibroGen
IPF
Flag link:
FibroGen initiates trial of cancer drug
FibroGen initiates trial of cancer drug
Bizjournals.com
FibroGen
cancer
Flag link: